Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 7/20 | 0.55 |
| ▸ | MAPT | P10636 | 7/20 | 0.55 |
| ▸ | MEN1 | O00255 | 5/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.55 |
| ▸ | ABHD5 | Q8WTS1 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.51 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.51 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | FBP1 | P09467 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16709336 | 0.89 | FBP1 (0.46) | LMNAMAPTMEN1KMT2APLIN1 | |
| SCHEMBL11405158 | 0.84 | LMNA (0.68) | LMNAMAPTMEN1KMT2APLIN1 | |
| SCHEMBL8131194 | 0.82 | MAPT (0.68) | LMNAMAPTMEN1KMT2APLIN1 | |
| SCHEMBL28461706 | 0.80 | HDAC3 (0.40) | LMNAMAPTMEN1KMT2APLIN1 | |
| SCHEMBL7833052 | 0.80 | MAPT (0.64) | LMNAMAPTMEN1KMT2APLIN1 | |
| SCHEMBL8651801 | 0.78 | MAPT (0.59) | LMNAMAPTMEN1KMT2APLIN1 | |
| SCHEMBL8651798 | 0.78 | MAPT (0.59) | LMNAMAPTMEN1KMT2APLIN1 | |
| SCHEMBL8432135 | 0.78 | MEN1 (0.66) | LMNAMAPTMEN1KMT2APLIN1 | |
| SCHEMBL19257215 | 0.78 | MAOB (0.48) | MAPTMEN1KMT2AFBP1KDM4E | |
| SCHEMBL396592 | 0.77 | KDM4E (0.66) | LMNAMAPTMEN1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9556204-B2 | Methods and intermediates for the preparation of (4bS,5aR)-12-cyclohexyl-N-(N,N-dimethylsulfamoyl)-3-methoxy-5a-((1R,5S)-3-methyl-3,8-diazabicyclo [3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-A]indole-9-carboxamide | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-31 | — | — | US | disclosed |
| US-9556204-B2 | Methods and intermediates for the preparation of (4bS,5aR)-12-cyclohexyl-N-(N,N-dimethylsulfamoyl)-3-methoxy-5a-((1R,5S)-3-methyl-3,8-diazabicyclo [3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-A]indole-9-carboxamide | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-31 | — | — | US | disclosed |
| US-9556204-B2 | Methods and intermediates for the preparation of (4bS,5aR)-12-cyclohexyl-N-(N,N-dimethylsulfamoyl)-3-methoxy-5a-((1R,5S)-3-methyl-3,8-diazabicyclo [3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-A]indole-9-carboxamide | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-31 | — | — | US | disclosed |
| EP-3091022-A2 | METHODS AND INTERMEDIATES FOR THE PREPARATION OF (4BS,5AR)-12-CYCLOHEXYL-N-(N,N-DIMETHYLSULFAMOYL)-3- METHOXY-5A-((1R,5S)-3-METHYL-3,8-DIAZABICYCLO[3.2.1]OCTANE-8-CARBONYL)-4B,5,5A,6-TETRAHYDROBENZO [3,4]CYCLOPROPA[5,6]AZEPINO[1,2-A]INDOLE-9-CARBOXAMIDE | Bristol-Myers Squibb Holdings Ireland (CH) | 2016-11-09 | — | — | EP | disclosed |
| EP-3091022-A2 | METHODS AND INTERMEDIATES FOR THE PREPARATION OF (4BS,5AR)-12-CYCLOHEXYL-N-(N,N-DIMETHYLSULFAMOYL)-3- METHOXY-5A-((1R,5S)-3-METHYL-3,8-DIAZABICYCLO[3.2.1]OCTANE-8-CARBONYL)-4B,5,5A,6-TETRAHYDROBENZO [3,4]CYCLOPROPA[5,6]AZEPINO[1,2-A]INDOLE-9-CARBOXAMIDE | Bristol-Myers Squibb Holdings Ireland (CH) | 2016-11-09 | — | — | EP | disclosed |
| EP-2875030-B1 | METHODS AND INTERMEDIATES FOR THE PREPARATION OF (4BS,5AR)-12-CYCLOHEXYL-N-(N,N-DIMETHYLSULFAMOYL)-3- METHOXY-5A-((1R,5S)-3-METHYL-3,8-DIAZABICYCLO[3.2.1]OCTANE-8-CARBONYL)-4B,5,5A,6-TETRAHYDROBENZO [3,4]CYCLOPROPA[5,6]AZEPINO[1,2-A]INDOLE-9-CARBOXAMIDE | BRISTOL MYERS SQUIBB HOLDINGS IRELAND (CH) | 2016-10-26 | — | — | EP | disclosed |
| EP-2875030-B1 | METHODS AND INTERMEDIATES FOR THE PREPARATION OF (4BS,5AR)-12-CYCLOHEXYL-N-(N,N-DIMETHYLSULFAMOYL)-3- METHOXY-5A-((1R,5S)-3-METHYL-3,8-DIAZABICYCLO[3.2.1]OCTANE-8-CARBONYL)-4B,5,5A,6-TETRAHYDROBENZO [3,4]CYCLOPROPA[5,6]AZEPINO[1,2-A]INDOLE-9-CARBOXAMIDE | BRISTOL MYERS SQUIBB HOLDINGS IRELAND (CH) | 2016-10-26 | — | — | EP | disclosed |
| EP-2875030-A1 | NOVEL METHODS AND INTERMEDIATES FOR THE PREPARATION OF (4BS,5AR)-12-CYCLOHEXYL-N-(N,N-DIMETHYLSULFAMOYL)-3-METHOXY-5A-((1 R,5S) -3-METHYL-3,8-DIAZABICYCLO[3.2.1]OCTANE-8-CARBONYL)-4B,5,5A,6-TETRAHYDROBENZO [3,4]CYCLOPROPA[5,6]AZEPINO[1,2-A]INDOLE-9-CARBOXAMIDE | Bristol-Myers Squibb Holdings Ireland (CH) | 2015-05-27 | — | — | EP | disclosed |
| US-20150133654-A1 | NOVEL METHODS AND INTERMEDIATES FOR THE PREPARATION OF (4bS,5aR)-12-CYCLOHEXYL-N-(N,N-DIMETHYLSULFAMOYL)-3-METHOXY-5a-((1R,5S)-3-METHYL-3,8-DIAZABICYCLO[3.2.1]OCTANE-8-CARBONYL)-4b,5,5a,6-TETRAHYDROBENZO [3,4]CYCLOPROPA[5,6]AZEPINO[1,2-A]INDOLE-9-CARBOXAMIDE | BRISTOL-MYERS SQUIBB COMPANY | 2015-05-14 | — | — | US | disclosed |
| US-20150133654-A1 | NOVEL METHODS AND INTERMEDIATES FOR THE PREPARATION OF (4bS,5aR)-12-CYCLOHEXYL-N-(N,N-DIMETHYLSULFAMOYL)-3-METHOXY-5a-((1R,5S)-3-METHYL-3,8-DIAZABICYCLO[3.2.1]OCTANE-8-CARBONYL)-4b,5,5a,6-TETRAHYDROBENZO [3,4]CYCLOPROPA[5,6]AZEPINO[1,2-A]INDOLE-9-CARBOXAMIDE | BRISTOL-MYERS SQUIBB COMPANY | 2015-05-14 | — | — | US | disclosed |
| US-20090162318-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-06-25 | — | — | US | disclosed |
| WO-2009067108-A1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-28 | — | — | WO | disclosed |
| US-7521443-B2 | 3,8-Diazabicyclo[3.2.1]octane-3-carboxylic acid, 8-[[8-cyclohexyl-5-[[[(dimethylamino)sulfonyl]amino]carbonyl]-1,12b-dihydro-11-methoxycycloprop[d]indolo[2,1-a][2]benzazepin-1a(2H)-yl]carbonyl]-, phenylmethyl ester; RNA polymerase inhibitor; liver disease, including cirrhosis and hepatocellular carcinoma | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-21 | — | — | US | disclosed |
| US-7521443-B2 | 3,8-Diazabicyclo[3.2.1]octane-3-carboxylic acid, 8-[[8-cyclohexyl-5-[[[(dimethylamino)sulfonyl]amino]carbonyl]-1,12b-dihydro-11-methoxycycloprop[d]indolo[2,1-a][2]benzazepin-1a(2H)-yl]carbonyl]-, phenylmethyl ester; RNA polymerase inhibitor; liver disease, including cirrhosis and hepatocellular carcinoma | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-21 | — | — | US | disclosed |
| US-7456166-B2 | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| US-20080146537-A1 | 3,8-Diazabicyclo[3.2.1]octane-3-carboxylic acid, 8-[[8-cyclohexyl-5-[[[(dimethylamino)sulfonyl]amino]carbonyl]-1,12b-dihydro-11-methoxycycloprop[d]indolo[2,1-a][2]benzazepin-1a(2H)-yl]carbonyl]-, phenylmethyl ester; RNA polymerase inhibitor; liver disease, including cirrhosis and hepatocellular carcinoma | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-19 | — | — | US | disclosed |
| US-20080146537-A1 | 3,8-Diazabicyclo[3.2.1]octane-3-carboxylic acid, 8-[[8-cyclohexyl-5-[[[(dimethylamino)sulfonyl]amino]carbonyl]-1,12b-dihydro-11-methoxycycloprop[d]indolo[2,1-a][2]benzazepin-1a(2H)-yl]carbonyl]-, phenylmethyl ester; RNA polymerase inhibitor; liver disease, including cirrhosis and hepatocellular carcinoma | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-19 | — | — | US | disclosed |
| WO-2007136982-A1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-29 | — | — | WO | disclosed |
| US-20070270405-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-11-22 | — | — | US | disclosed |
| US-20070270405-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270405-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | HAVCR2, ZC3HAV1, HCCS | LMNA 3938/4885MAPT 3833/4885MEN1 4862/4885 |
| US-20080146537-A1 | 3,8-Diazabicyclo[3.2.1]octane-3-carboxylic acid, 8-[[8-cyclohexyl-5-[[[(dimethylamino)sulfonyl]amino]carbonyl]-1,12b-dihydro-11-methoxycycloprop[d]indolo[2,1-a][2]benzazepin-1a(2H)-yl]carbonyl]-, phenylmethyl ester; RNA polymerase inhibitor; liver disease, including cirrhosis and hepatocellular carcinoma | ZC3HAV1, ODC1, MED1 | LMNA 241/4885MAPT 4710/4885MEN1 4057/4885 |
| US-20150133654-A1 | NOVEL METHODS AND INTERMEDIATES FOR THE PREPARATION OF (4bS,5aR)-12-CYCLOHEXYL-N-(N,N-DIMETHYLSULFAMOYL)-3-METHOXY-5a-((1R,5S)-3-METHYL-3,8-DIAZABICYCLO[3.2.1]OCTANE-8-CARBONYL)-4b,5,5a,6-TETRAHYDROBENZO [3,4]CYCLOPROPA[5,6]AZEPINO[1,2-A]INDOLE-9-CARBOXAMIDE | HTR3C, HTR2C, HTR1B | LMNA 1848/4885MAPT 4256/4885MEN1 3806/4885 |
| US-20090162318-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | HAVCR2, ZC3HAV1, HCCS | LMNA 3938/4885MAPT 3833/4885MEN1 4862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.